

Avner Shemer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11743880/publications.pdf>

Version: 2024-02-01

68
papers

4,971
citations

172207

29
h-index

114278

63
g-index

70
all docs

70
docs citations

70
times ranked

4689
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic approach to tinea capitis with kerion: A retrospective study. <i>Pediatric Dermatology</i> , 2022, 39, 708-712.	0.5	1
2	Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study. <i>Dermatology</i> , 2021, 237, 902-906.	0.9	4
3	Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 310-313.	1.1	6
4	Management of tinea capitis in Israel: A comparative study. <i>Pediatric Dermatology</i> , 2021, 38, 806-811.	0.5	5
5	Low-dose isotretinoin versus minocycline in the treatment of rosacea. <i>Dermatologic Therapy</i> , 2021, 34, e14986.	0.8	4
6	High prevalence of mixed infections in global onychomycosis. <i>PLoS ONE</i> , 2020, 15, e0239648.	1.1	32
7	Once Weekly Application of Urea 40% and Bifonazole 1% Leads to Earlier Nail Removal in Onychomycosis. <i>Skin Appendage Disorders</i> , 2020, 6, 304-308.	0.5	6
8	Cold sub-atmospheric and atmospheric pressure plasma for the treatment of <i>Trichophyton rubrum</i> onychomycosis: An in vitro study. <i>Dermatologic Therapy</i> , 2020, 33, e14084.	0.8	1
9	Clinical significance of <i>Candida</i> isolation from dystrophic fingernails. <i>Mycoses</i> , 2020, 63, 964-969.	1.8	0
10	Global perspectives for the management of onychomycosis. <i>International Journal of Dermatology</i> , 2019, 58, 1118-1129.	0.5	39
11	Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. <i>Experimental Dermatology</i> , 2019, 28, 35-44.	1.4	15
12	Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 305-308.e6.	1.5	29
13	A Retrospective Study Comparing K101 Nail Solution as a Monotherapy and in Combination with Oral Terbinafine or Itraconazole for the Treatment of Toenail Onychomycosis. <i>Skin Appendage Disorders</i> , 2018, 4, 166-170.	0.5	4
14	Variability in Systemic Treatment Efficacy for Onychomycosis: Information That Clinical Studies Do Not Impart to the Office Dermatologist. <i>Skin Appendage Disorders</i> , 2018, 4, 141-144.	0.5	8
15	Painful Nail. , 2018, , 287-301.		2
16	Fungal Infections (Onychomycosis, Tinea Pedis, Tinea Cruris, Tinea Capitis, Tinea Manuum, Tinea) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 J Analyses. , 2018, , 235-242.		5
17	Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. <i>Dermatologic Therapy</i> , 2017, 30, e12545.	0.8	19
18	An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. <i>Journal of Investigative Dermatology</i> , 2017, 137, 603-613.	0.3	156

#	ARTICLE	IF	CITATIONS
19	Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. <i>Experimental Dermatology</i> , 2017, 26, 272-275.	1.4	11
20	Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0148450.	1.1	33
21	Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2030-2040.	0.3	33
22	Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1251-1252.	0.6	23
23	Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. <i>Mycopathologia</i> , 2016, 181, 851-856.	1.3	21
24	Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. <i>Experimental Dermatology</i> , 2016, 25, 282-286.	1.4	62
25	Petrolatum: Barrier repair and antimicrobial responses underlying this inert moisturizer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1091-1102.e7.	1.5	126
26	Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 118-129.e5.	1.5	96
27	Onychomycosis in Israel: epidemiological aspects. <i>Mycoses</i> , 2015, 58, 133-139.	1.8	29
28	Griseofulvin and Fluconazole Reduce Transmission of Tinea Capitis in Schoolchildren. <i>Pediatric Dermatology</i> , 2015, 32, 696-700.	0.5	6
29	Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 712-720.	1.5	55
30	The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. <i>Journal of Dermatological Science</i> , 2015, 77, 74-76.	1.0	50
31	Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 104-115.e7.	1.5	183
32	Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 208-211.	1.5	69
33	Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 941-951.e3.	1.5	175
34	Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1277-1287.	1.5	176
35	Betamethasone valerate foam: a look at the clinical data. <i>Clinical Investigation</i> , 2014, 4, 259-267.	0.0	2
36	Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1626-1634.	1.5	146

#	ARTICLE	IF	CITATIONS
37	Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 955-957.	1.5	20
38	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 362-372.	1.5	224
39	Treatment of tinea capitis " griseofulvin versus fluconazole " a comparative study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 737-741.	0.4	9
40	Autoimmune Disease Induction in a Healthy Human Organ: A Humanized Mouse Model of Alopecia Areata. <i>Journal of Investigative Dermatology</i> , 2013, 133, 844-847.	0.3	65
41	Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 577-579.	1.5	27
42	Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 361-370.	1.5	402
43	Common nail disorders. <i>Clinics in Dermatology</i> , 2013, 31, 578-586.	0.8	36
44	Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 498-501.e3.	1.5	39
45	Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2088-2091.	0.3	27
46	Therapie der Tinea capitis " Griseofulvin versus Fluconazol " eine vergleichende Studie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 737-742.	0.4	16
47	Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1344-1354.	1.5	731
48	Update: medical treatment of onychomycosis. <i>Dermatologic Therapy</i> , 2012, 25, 582-593.	0.8	44
49	Onychomycosis: a simpler in-office technique for sampling specimens. <i>Journal of Family Practice</i> , 2012, 61, 552-4.	0.2	2
50	Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 954-964.e4.	1.5	375
51	Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 583-593.e4.	1.5	182
52	Iontophoretic Terbinafine HCL 1.0% Delivery Across Porcine and Human Nails. <i>Mycopathologia</i> , 2010, 169, 343-349.	1.3	27
53	Ciclopirox nail lacquer for the treatment of onychomycosis: An open non-comparative study. <i>Journal of Dermatology</i> , 2010, 37, 137-139.	0.6	20
54	Comparative study of nail sampling techniques in onychomycosis. <i>Journal of Dermatology</i> , 2009, 36, 410-414.	0.6	17

#	ARTICLE	IF	CITATIONS
55	Onychomycosis in psoriatic patients - rationalization of systemic treatment. <i>Mycoses</i> , 2009, 53, 340-3.	1.8	14
56	IL-22-producing T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1244-1252.e2.	1.5	547
57	Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1235-1244.e58.	1.5	231
58	Onychomycosis: rationalization of topical treatment. <i>Israel Medical Association Journal</i> , 2008, 10, 415-6.	0.1	14
59	Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. <i>Israel Medical Association Journal</i> , 2008, 10, 417-8.	0.1	22
60	Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 1108-1111.	0.4	13
61	Nagelproben bei Onychomykose:Vergleichsstudie mit einer Kurettage an drei Stellen des infizierten Nagels. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, no.	0.4	0
62	Emollient foam in topical drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 799-807.	2.4	32
63	The Hyper-IgE Syndrome. Two cases and review of the literature. <i>International Journal of Dermatology</i> , 2001, 40, 622-628.	0.5	31
64	Wells' syndrome: report of a case and review of the literature. <i>International Journal of Dermatology</i> , 2001, 40, 148-152.	0.5	24
65	Wells' syndrome: report of a case and review of the literature. , 2001, 40, 148.		2
66	Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. <i>International Journal of Dermatology</i> , 2000, 39, 532-534.	0.5	35
67	Diabetic dermopathy and internal complications in diabetes mellitus. <i>International Journal of Dermatology</i> , 1998, 37, 113-115.	0.5	85
68	Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. <i>International Journal of Dermatology</i> , 1997, 36, 67-69.	0.5	26